secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2022-08-05T23:59:59+00:00
Accession:  0001104659-22-086454
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis reports Q2 2022 net loss of $3.6M; cash $13.6M; pipeline advances
--------------------------------------------------------------------------

- Cash and investments $13.6M at June 30, 2022, up from $5.7M at Dec 31, 2021, driven by IPO.
- Net loss of $3.6M for Q2 2022, narrowed from $5.9M in Q2 2021 due to lower R&D and G&A.
- NXP800 Phase 1a dose-escalation ongoing; Phase 1b expansion expected Q1 2023; FDA cleared IND, U.S. and U.K. enrolling.
- NXP900 IND-enabling studies on track for 2022 completion; preclinical data in medulloblastoma presented.
- Completed $15.9M private placement in August 2022, extending cash runway into H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465922086454/0001104659-22-086454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465922086454/tm2222617d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-086454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer